Alain Vertes | Managing Director
NxR Biotechnologies

Alain Vertes, Managing Director, NxR Biotechnologies

Dr Alain Vertès is a Sloan Fellow from London Business School and a microbiologist by training (University of Illinois at Urbana-Champaign, Institut Pasteur Paris, and University of Lille Flandres-Artois). He is a strategy and business development consultant for several companies, including big pharma and cell therapeutic biotechs, and works to enable seed funding in the field. Focusing on technology deployment and innovation commercialization, and with a strong international exposure, he gained valuable experience in managing strategic alliances and was a key player in the evaluation, selection, deal making, and implementation of novel technologies to further advance the drug discovery research paradigm. He has contributed to both white (industrial) and red (pharmaceutical) biotechnology, in different functions including research, manufacturing, contract research (Battelle Memorial Institute, Pharmaceutical Product Development/BioDuro), and strategic alliances in pharmaceuticals (Lilly, Pfizer, Roche), petrochemicals (Mitsubishi Chemical Corporation), biotechnology (Mesoblast), public research, and consulting (Australian Strategic Policy Institute, NxR Biotechnologies GmbH). Particularly, he has long been associated with the Research Institute of Innovative Technology for the Earth in Kyoto, Japan, working on developing transformational biorefinery technologies and on deploying green technologies to the marketplace. In the pharmaceutical industry, he was for example global alliance director at Roche in the partnering group identifying strategic needs, finding, implementing and managing partnerships from licensing to mergers and acquisitions. Notably, he championed radical innovation for bringing to patients disease-modifying, paradigm-changing therapeutics such as siRNA, and led in a scientific and business manner Roche’s global cell therapeutics strategy and implementation team resulting in Roche’s entry in the field of regenerative medicine.


Advanced Therapies and Regenerative Medicine Day 1 - Wednesday 16th May 2018 @ 13:00

Networking Lunch

Seminar Theatre 13:00-13:40 Panel discussion: exploring the crossover between human and veterinary applications for stem cells: 

Seminar Theatre 14:00-14:20 Talk: Strategies for preserving cell loss in animal models and humans

Roger Smith, Professor, Equine Orthopaedics, Royal Veterinary College (RVC)

Advanced Therapies and Regenerative Medicine Day 2 - Thursday 17th May 2018 @ 08:50

Chair: Alain Vertès, Managing Director, NxR Biotechnologies

Advanced Therapies and Regenerative Medicine Day 2 - Thursday 17th May 2018 @ 12:00

Cellular medicines for intractable serious and life-threatening diseases

  •     Disruptive cellular technology platforms
  •     Commercial translation capabilities
  •     Advanced pipeline of cellular medicines targeting serious or life-threatening conditions with unmet needs 

back to speakers



Erica Baeta
+44 (0)207 092 1152


Jessica Robinson
t/ +44 (0)207 092 1150


Issa Mauthoor
+44 (0)207 092 1257